• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A leading pure play vaccine company.


— April 18, 2017

Valneva Announces Signing of a New EB66® Commercial License with Bavarian Nordic

Read more

— Stock information


— December 9, 2016
Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate

Read more
— Financial Calendar

May 11, 2017
Q1 2017 Interim Results

June 29, 2017
Annual General Meeting 2017

See all dates

KOL event in N.Y. on Lyme disease (webcast)


learn more
play video Valneva's CEO Thomas Lingelbach
comments on Group Strategy

– Upcoming conferences and fairs

Euronext Tech Investor Forum
Frankfurt, Germany
April 27, 2017

Gilbert Dupont Midcap Healthcare Forum
Paris, France
May 30, 2017

Jefferies 2017 Global Healthcare Conference
New York, US
June 6-9, 2017

Kepler Biotech Days
Paris, France
June 8-9, 2017

Please update your browser...